| Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis. | |
| | |
MedLine Citation:
|
PMID: 18276604 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: To establish a cefozopran (a fourth-generation cephem) population pharmacokinetic model using patient data and use it to explore alternative dosage regimens that could optimize the currently used dosing regimen to achieve higher likelihood of pharmacodynamic exposure against pathogenic bacteria. METHODS: We conducted a prospective clinical trial of cefozopran for haematological patients with febrile neutropenia (FN). Twenty-two patients (30 episodes) were selected to receive intravenous cefozopran every 8 h on a daily basis. We gathered concentration data and performed the NONMEM program. The Monte Carlo simulation was performed to assess the pharmacodynamic exposure based on the population pharmacokinetics and MIC. RESULTS: The NONMEM program demonstrated that a two-compartment model provided a best fit for the data, that is, CL of 4.62 (L/h), V1 of 10.3 (L), Q of 4.47 (L/h), and V2 of 4.48 (L). On the basis of the Japanese national surveillance findings for Pseudomonas aeruginosa, methicillin-sensitive Staphylococcus aureus, coagulase-negative Staphylococcus, viridans group streptococci, Escherichia coli and Klebsiella pneumoniae, Monte Carlo simulation data showed that probability of target attainment(T>MIC = 70%) is 67% to 97% for dosing every 8 h, and 48% to 88% for dosing every 12 h. For the patients in whom the efficacy of cefozopran could be evaluated, 17 of 22 patients (77.2%) survived the episode of FN without requiring further antibacterial treatment. CONCLUSIONS: Our study proved that Monte Carlo simulation based on population pharmacokinetics can determine optimized dosage and method. The optimal regimen for this cephem was found to be three times daily. |
| | |
Authors:
|
Kenichi Nomura; Norifumi Morikawa; Kazuro Ikawa; Kayo Ikeda; Yoshiko Fujimoto; Daisuke Shimizu; Kyoko Taniguchi; Kazuho Shimura; Yuko Kanbayashi; Toshiaki Komori; Yosuke Matsumoto; Naohisa Fujita; Chihiro Shimazaki; Masafumi Taniwaki |
Related Documents
:
|
6329584 - Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pha... 10209814 - Bootstrap approach for constructing confidence intervals for population pharmacokinetic... 18043484 - Limited sampling strategies to estimate exposure to the green tea polyphenol, epigalloc... 6760474 - A randomized-blinded evaluation of analytical error associated with the enzyme immunoas... 19278664 - The metapopulation fitness criterion: proof and perspectives. 4096774 - A technique for lateral retinacular release. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't Date: 2008-02-13 |
Journal Detail:
|
Title: The Journal of antimicrobial chemotherapy Volume: 61 ISSN: 1460-2091 ISO Abbreviation: J. Antimicrob. Chemother. Publication Date: 2008 Apr |
Date Detail:
|
Created Date: 2008-03-19 Completed Date: 2008-04-15 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7513617 Medline TA: J Antimicrob Chemother Country: England |
Other Details:
|
Languages: eng Pagination: 892-900 Citation Subset: IM |
Affiliation:
|
Department of Haematology and Oncology, Kyoto Prefectural University of Medicine Graduate School of Medical Sciences, Kyoto, Japan. nomuken@koto.kpu-m.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Anti-Bacterial Agents / administration & dosage*, pharmacokinetics, therapeutic use* Bacteria / drug effects Bacterial Infections / drug therapy* Cephalosporins / administration & dosage*, pharmacokinetics, therapeutic use* Female Fever / drug therapy* Hematologic Neoplasms / complications Humans Male Microbial Sensitivity Tests Middle Aged Models, Statistical Monte Carlo Method Neutropenia / drug therapy* Plasma / chemistry |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents; 0/Cephalosporins; 113359-04-9/cefozopran |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Micafungin combined with fluconazole, an effective therapy for murine blastoschizomycosis.
Next Document: Medical education reform efforts and failures of U.S. medical schools, 1870-1930.